Source:		MedGen UID: 202507

     		Interferon Beta-1A

			A synthetic version of naturally occurring
			interferons that have immunomodulatory,
			antiviral and antiproliferative activities. It may
			exert antitumor activity by anti-angiogenic and
			cell differentiation activities. (NCI)

			PRJNA120367 Expression data of multiple
			sclerosis patients receiving intramuscular
			Interferon-beta-1a therapy [U133 A and B]

			PRJNA148781 Expression data of multiple
			sclerosis patients receiving subcutaneous
			Interferon-beta-1a therapy [U133 Plus 2.0]

			PRJNA111357 Interferon beta-1a-induced
			changes in gene expression in PBMCs derived
			from CIS patients

			PRJNA297802 Transcriptional response to
			interferon beta-1a treatment in patients with
			secondary progressive multiple sclerosis

			PRJNA99075 Whole Genome Microarray
			comparison of two Interferon Beta 1a
			Pharmaceutical Preparations

			31026608 Successful intravenous
			immunoglobulin treatment in relapsing
			MOG-antibody-associated disease.

			30967831 Best Practices for Long-Term
			Monitoring and Follow-Up of
			Alemtuzumab-Treated MS Patients in
			Real-World Clinical Settings.

			30944584 Real-life outcomes of teriflunomide
			treatment in patients with relapsing multiple
			sclerosis: TAURUS-MS observational study.

			30917079 The Impact of Price Reductions
			After Loss of Exclusivity in a Cost-Effectiveness
			Analysis: Fingolimod Versus Interferon Beta-1a
			for the Treatment of Relapsing-Remitting
			Multiple Sclerosis.

			30886679 Pegylated versus non-pegylated
			interferon beta 1a in patients with
			relapsing-remitting multiple sclerosis: A
			cost-effectiveness analysis.

			30820880 Assessing the Metabolomic Profile
			of Multiple Sclerosis Patients Treated with
			Interferon Beta 1a by 1H-NMR Spectroscopy.

			30800548 Tumefactive Multiple Sclerosis, A
			Rare Variant Presenting as Multiple
			Ring-enhancing Lesions in an
			Immunocompetent Patient: A Case Report.

			30785358 Immune thrombocytopenia in
			alemtuzumab-treated MS patients: Incidence,
			detection, and management.

			30763907 Tolerability, treatment satisfaction
			and quality of life outcomes in stable multiple
			sclerosis patients switched from injectable
			therapies to auto injected intramuscular
			interferon beta 1a: The SFERA study.

			30729026 Patients transitioning from
			non-pegylated to pegylated interferon beta-1a
			have a low risk of new flu-like symptoms:
			ALLOW phase 3b trial results.

			30702002 Modulating acute neuroinflammation
			in intracerebral hemorrhage: the potential
			promise of currently approved medications for
			multiple sclerosis.

			30574342 A real-world comparison of relapse
			rates, healthcare costs and resource use
			among patients with multiple sclerosis newly
			initiating subcutaneous interferon beta-1a
			versus oral disease-modifying drugs.


			30522373 Cost-utility analysis of alemtuzumab
			in comparison with interferon beta, fingolimod,
			and natalizumab treatment for
			relapsing-remitting multiple sclerosis in Austria.

			30460997 Identifiability of biologicals in adverse
			drug reaction reports received from European
			clinical practice.

			30315901 Uveitis in Patients with Multiple
			Sclerosis in Clinical Trials of Fingolimod:
			Incidence, Prevalence and Impact on Disease

			30289355 Infection risk with alemtuzumab
			decreases over time: pooled analysis of 6-year
			data from the CAMMS223, CARE-MS I, and
			CARE-MS II studies and the CAMMS03409
			extension study.

			30270137 Inflammatory demyelinating diseases
			of the central nervous system in Niger.

			30229541 Pediatric Multiple Sclerosis: an

			30217172 Effect of interferon beta-1a
			subcutaneously three times weekly on clinical
			and radiological measures and no evidence of
			disease activity status in patients with
			relapsing-remitting multiple sclerosis at year 1.

			Clinical Trials
			3614715 Pharmacokinetics and
			Pharmacodynamics of CinnoVex (Interferon
			Beta-1a) Compared to Avonex (Interferon

			3424733 Evaluating the Use of Prednisone to
			Decrease Pegylated Interferon Beta-1a Side

			3284970 Retrospective Study to Determine
			Effect of Rebif and Tecfidera on Infections and

			3119701 Efficacy and Safety of FP-1201-lyo
			(Interferon Beta-1a) in Prevention of MOF on
			Patients After Open Surgery for a RAAA

			2622724 Efficacy and Safety of FP-1201-lyo
			(Interferon Beta-1a) in Patients Having Acute
			Respiratory Distress Syndrome (ARDS)

			2517788 Phase I BP Interferon (IFN) Beta-004

			2515695 Phase I BP Interferon (IFN) Beta-001

			2491684 A Study in Asthma Patients to
			Evaluate Efficacy, Safety and Tolerability of 14
			Days Once Daily Inhaled Interferon Beta-1a
			After the Onset of Symptoms of an Upper
			Respiratory Tract Infection

			2394782 Observational Study of Rebismart®2.0
			+ MSdialog™ in Subjects With Remitting Multiple
			Sclerosis (ADHERQOL)

			2364986 Immune- and miRNA-response to
			Recombinant Interferon Beta in Healthy
			Volunteers and Patients With Relapsing
			Remitting Multiple Sclerosis

			2359877 Open Label Study of Tolerability,
			Pharmacokinetics and Pharmacodynamics of
			BCD-054 (Pegylated Interferon Beta-1a), IM
			and SC, Compared to Rebif® and Avonex® in
			Healthy Volunteers

			2254304 Effectiveness of Rebif® in Clinically
			Isolated Syndrome and Relapsing Multiple
			Sclerosis Using RebiSmart™

			2236624 Aerobic Exercise and Flu-like
			Symptoms Following Interferon Beta 1a
			Injections in Patients With Multiple Sclerosis?

			2125578 A Multiple Dose Safety Study of
			PEG-IFN in Healthy Volunteers

			2064816 A Study of Rebif® in Subjects With
			Relapsing Multiple Sclerosis

			1911767 Biogen Multiple Sclerosis Pregnancy
			Exposure Registry

			1892722 Safety and Efficacy of Fingolimod in
			Pediatric Patients With Multiple Sclerosis

			1863069 Avonex®: Safety, Blood Levels and

			1766024 Pharmacokinetics and
			Pharmacodynamics Study of BCD-033
			Compared to Rebif® in Healthy Volunteers

			1717664 Proof of Concept Study of RHB-104
			as Add-On Therapy to Interferon Beta-1a in
			Relapsing Remitting Multiple Sclerosis (RRMS)

     		                         Embed       Tweet       Print